Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIKING-4: Dolutegravir in INI-Resistant HIV-1
NCT01568892Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Apr 2012
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dolutegravir in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Started Apr 2012; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01568892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01568892.